Artiva Biotherapeutics, Inc.
Income Statement
| Line Item | Mar 2024 | Sep 2023 | Jun 2023 |
|---|---|---|---|
| Revenue | $251.0K | $26.7M | $3.5M |
| Cost of Revenue | — | — | — |
| Gross Profit | — | — | — |
| Gross Margin | — | — | — |
| Operating Expenses | |||
| Research & Development | $11.2M | $13.1M | $11.3M |
| SG&A Expense | $3.6M | $2.8M | $4.1M |
| Operating Income | $-14.5M | $10.8M | $-11.8M |
| Operating Margin | -5,773.7% | 40.6% | -338.1% |
| Interest Expense | — | — | — |
| Pretax Income | — | — | — |
| Income Tax Expense | — | — | — |
| Net Income | $-14.0M | $11.3M | $-11.3M |
| Net Margin | -5,562.9% | 42.3% | -322.7% |
| EPS (Basic) | $-0.62 | $0.50 | $-0.50 |
| EPS (Diluted) | $-0.62 | $0.06 | $-0.50 |
| Shares Outstanding (Basic) | 22.7M | 22.6M | 22.4M |
| Shares Outstanding (Diluted) | 22.7M | 195.1M | 22.4M |
| Dividends Per Share | — | — | — |